Skip to main content

Peer Review reports

From: Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China

Original Submission
5 May 2023 Submitted Original manuscript
3 Jun 2023 Reviewed Reviewer Report - Markus Reiser
3 Jul 2023 Reviewed Reviewer Report
10 Jul 2023 Reviewed Reviewer Report - Chun-Ming Hong
15 Oct 2023 Author responded Author comments - Chaoshuang Lin
18 Oct 2023 Author responded Author comments - Chaoshuang Lin
Resubmission - Version 2
15 Oct 2023 Submitted Manuscript version 2
30 Oct 2023 Reviewed Reviewer Report
1 Nov 2023 Reviewed Reviewer Report - Chun-Ming Hong
9 Dec 2023 Author responded Author comments - Chaoshuang Lin
Resubmission - Version 3
9 Dec 2023 Submitted Manuscript version 3
17 Jan 2024 Reviewed Reviewer Report
19 Jan 2024 Reviewed Reviewer Report - Chun-Ming Hong
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
24 Jan 2024 Editorially accepted
14 Feb 2024 Article published 10.1186/s12876-024-03147-5

You can find further information about peer review here.

Back to article page